"Regenstrief has a passion for determining how personalization of medicine can be achieved by better understanding and using health data,"
WHITEHOUSE, N.J., and INDIANAPOLIS--(BUSINESS WIRE)--The Regenstrief Institute and Merck, known as MSD outside the United
States and Canada, have signed a five-year agreement to collaborate on a
range of projects that will use clinical data to inform personalized
delivery of health care. The work will explore novel methods for
studying diseases and interventions for chronic conditions such as
diabetes, cardiovascular disease and osteoporosis.
Ultimately, the Regenstrief-Merck collaboration seeks to improve the
health of patients through data analytics, health care innovation,
education and research that supports evidence-based health care.
Financial details were not disclosed.
“Regenstrief has a passion for determining how personalization of
medicine can be achieved by better understanding and using health data,”
said Regenstrief investigator and innovations officer Jon Duke, M.D.,
who serves as the institute’s lead investigator for the partnership.
“Regenstrief brings rigorous science to clinical environments and has
more than 40 years of experience as an international leader in improving
health care delivery through informatics and health services research.
With Merck’s depth of expertise and its global reach, we hope to develop
and test new approaches to care, and advance successful models of health
care broadly.” Dr. Duke also is an assistant professor of medicine at
the Indiana University School of Medicine.
Both Regenstrief, a medical research organization closely associated
with the Indiana University School of Medicine, and Merck, a global
health care leader, are committed to generating new knowledge to improve
"This type of novel academic-industry collaboration can advance our
understanding of a number of critical therapeutic areas, enabling novel
use of health information technology to enhance drug development,
medication safety and the personalization of therapeutics," said Sachin
H. Jain, M.D., chief medical information and innovation officer at Merck.
An internationally respected informatics and health care research
organization, the Regenstrief Institute is recognized for its role in
improving quality of care, increasing efficiency of health care
delivery, preventing medical errors and enhancing patient safety.
Established in 1969, the institute is closely associated with the
Indiana University School of Medicine and the Health and Hospital
Corporation of Marion County.
Today's Merck is a global health care leader working to help the world
be well. Merck is known as MSD outside the United States and
Canada. Through our prescription medicines, vaccines, biologic
therapies, and consumer care and animal health products, we work with
customers and operate in more than 140 countries to deliver innovative
health solutions. We also demonstrate our commitment to increasing
access to health care through far-reaching policies, programs and
partnerships. For more information, visit www.merck.com
and connect with us on Twitter, Facebook and YouTube.
Merck Forward-Looking Statement
This news release includes “forward-looking statements” within the
meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. Such statements may include,
but are not limited to, statements about the benefits of the merger
between Merck and Schering-Plough, including future financial and
operating results, the combined company’s plans, objectives,
expectations and intentions and other statements that are not historical
facts. Such statements are based upon the current beliefs and
expectations of Merck’s management and are subject to significant risks
and uncertainties. Actual results may differ from those set forth in the
The following factors, among others, could cause actual results to
differ from those set forth in the forward-looking statements: the
possibility that all of the expected synergies from the merger of Merck
and Schering-Plough will not be realized, or will not be realized within
the expected time period; the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; Merck’s ability to accurately predict future market
conditions; dependence on the effectiveness of Merck’s patents and other
protections for innovative products; and the exposure to litigation
and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ
materially from those described in the forward-looking statements can be
found in Merck’s 2011 Annual Report on Form 10-K and the company’s other
filings with the Securities and Exchange Commission available at the
SEC’s Internet site, www.sec.gov.
Media: Merck Caroline Lappetito, 267-305-7639 or Regenstrief Inst Cindy Fox Aisen, 317-843-2276 or Investor Relations: Merck Alex Kelly, 908-423-5185